AzTrials
AzTrials

PregnancyPhase 2NCT01466530

Sublingual Misoprostol & Isoflurane During Caesarean Section

A Phase 2 study testing Misoprostol in people with Pregnancy and Cesarean Delivery, run by Mansoura University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Misoprostol would reduce the uterine bleeding after caesarean delivery, without harmful effects on either mother or baby. The investigators postulated that the use of sublingual misoprostol during isoflurane anaesthesia for uncomplicated caesarean delivery would reduce maternal haemorrhage, uterine atonic effects, and… Read more about this study

Who is it for?
Ages 18 to 35 years, women only
Conditions the study is for
Pregnancy, Cesarean Delivery
What is being tested?
Misoprostol
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
366 participants
Where
1 siteEgypt
Study dates
Jan 2006to Sep 2011
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • American Society of Anesthesiologists class I and II
  • parturients aged 18-35 years
  • uncomplicated singleton pregnancies
  • Gestational age >= 36 weeks
  • elective caesarean delivery
  • refused regional anaesthesia
  • requested general anaesthesia.

Who cannot join

  • allergy to prostaglandins
  • bronchial asthma
  • anaemia
  • bleeding disorders
  • cardiac diseases
  • inflammatory bowel diseases
Show all 16Show fewer
  • multiple pregnancies
  • preeclampsia
  • placenta praevia
  • abruptio placenta
  • previous postpartum haemorrhage
  • antepartum haemorrhage
  • grand multiparity
  • uterine fibroids
  • intrauterine growth restriction
  • fetal abnormality

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • College of Medicine, Mansoura University

    Al Mansurah, DK, 050

Other trials in Egypt

About this study

Official title: Effects of Preoperative Sublingual Misoprostol on Uterine Tone During Isoflurane Anaesthesia for Caesarean Section

Misoprostol would reduce the uterine bleeding after caesarean delivery, without harmful effects on either mother or baby. The investigators postulated that the use of sublingual misoprostol during isoflurane anaesthesia for uncomplicated caesarean delivery would reduce maternal haemorrhage, uterine atonic effects, and the need for additional uterotonic agents, without harmful effects on either mother or baby. Therefore, the present study was designed to evaluate the effects of preoperative sublingual misoprostol on maternal blood loss, uterine tone, the need for additional oxytocin and neonatal outcome after elective caesarean delivery under isoflurane anaesthesia.

Read the detailed description

Volatile anaesthetics including sevoflurane, desflurane, and isoflurane are often used during general anaesthesia for caesarean delivery. The cost effectiveness of isoflurane anaesthesia1 for caesarean delivery is widely used at many centres including the authors' centre, where general anaesthesia is commonly used for caesarean deliveries than did regional anaesthesia because of the refusal of many ladies for the later, especially in the light of evidence-based equivocal maternal or neonatal outcomes of both techniques. 2 However, isoflurane in similar to other inhalational anaesthetics have been shown a dose-dependent (from 0.5 to 2.35 minimum alveolar concentration (MAC)) induced myometrial relaxation in 25% of parturients with added risks of postpartum haemorrhage, 3-5 which may be mediated through the inhibition of the oxytocin-induced contraction,6 decrease in intracellular concentration of free calcium,7 inhibition of voltage-dependent calcium channels activity,8 and activation of adenosine triphosphate-sensitive potassium channels (K (ATP))9 of pregnant uterine smooth muscle.

Several uterotonics such as oxytocin reduce postpartum haemorrhage by inducing uterine contraction, but with added risks of haemodynamic adverse effects. 10 Sublingual or rectal misoprostol, a prostaglandin E1 analogue, in doses of 100 to 800 µg is safe and as effective as intravenous infusion of oxytocin in reducing blood loss and the need for additional oxytocin after caesarean delivery under either spinal or general anaesthesia, with occurrence of transient side effects such as nausea, shivering and pyrexia. 11-17 Misoprostol possess several advantages over oxytocin, including long shelf life, stability at room temperature, and possible buccal, rectal and sublingual administration. 11, 16The later has many advantages such as rapid uptake, long-lasting duration of effect, and greatest bioavailability, compared with other routes of misoprostol administration. 18 Up to our best knowledge, this trial was the first one studied the inhibitory effects of misoprostol on the uterine atonic effects of inhalational anaesthetics.

Based upon previous published data, 19 blood loss after caesarean delivery was normally distributed with standard deviation 560 ml. A priori power analysis indicated that 174 patients in each group would be sufficient to detect a 20% reduction in blood loss after caesarean delivery, with a type-I error of 0.05 and a power of 90%. The investigators added 10% more patients to account for patients dropping out during the study.

Patients were randomly allocated to receive sublingual 400 µg of misoprostol or identical placebo two tablets after tracheal intubation before surgery.

Anaesthetic management was standardized in all studied patients. Oral ranitidine 150 mg was given the night before and on the morning of surgery, with 0.3 mol/L sodium citrate (30 mL) given 15 min before induction. In the operating theatre women were positioned supine on the operating table with 15° firm rubber wedge under the right hip to effect left uterine displacement. A slow 500-mL i.v. infusion of lactated Ringer's solution was given to all subjects over 20 min.

Subjects were monitored with electrocardiography, non-invasive blood pressure, pulse oximetry (SpO2), and end-tidal carbon dioxide concentration (EtCO2). After pre-oxygenation for 5 min, rapid-sequence induction was performed with propofol 1.5-2 mg/kg followed by suxamethonium 1.5 mg/kg after loss of verbal response. Cricoid pressure was applied after loss of consciousness and was released after correct placement of the tracheal tube had been confirmed.

After tracheal intubation, subjects were allocated randomly to two groups by drawing sequentially numbered sealed opaque envelopes containing a software-generated randomisation code (Random Allocation Software, version 1.0.0, Isfahan University of Medical Sciences, Isfahan, Iran). The parturients in the placebo group (n = 183) received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet. In the misoprostol group (n = 183), sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet). The anaesthesiologists who gave the anaesthetics and study tablets were blinded to the study randomization and were not involved in collecting of the patients' data. All staff in the operating room were unaware of the randomization code.

Anaesthesia was maintained with 0.5-1 MAC of isoflurane with nitrous oxide 50% in oxygen to maintain the heart rate and blood pressure within 20% of baseline values. Neuromuscular block was maintained with vecuronium 0.06 mg/kg. The lungs were ventilated using a tidal volume of 8 mL/kg, an inspiration-expiration ratio of 1: 2, and at a respiratory rate necessary to maintain an EtCO2 of 30-35 mm Hg. An infusion of lactated Ringer's solution 800 mL was given to all subjects during the procedure. Induction to delivery (I-D) times was recorded using a stopwatch.

After the umbilical cord was clamped, a 10-unit infusion of oxytocin in 500 mL of 5% glucose was started. Intravenous midazolam 0.05 mg/kg and fentanyl 2.0 µg/kg were given and end-tidal concentration of the nitrous oxide was increased to 70%.

The obstetrician who was blinded to the study group, assessed the uterine tone by palpation every three minutes after delivery of the placenta and rated the degree of uterine contraction on a 10-cm VAS (0: well contracted; 10: completely relaxed). If uterine tone remained unsatisfactory after 3 min, an additional 5-unit bolus of oxytocin was administered.

All neonates were assessed by a paediatrician unaware of the randomisation code as regarding their Apgar scores at 1 and 5 min, arterial blood pressure, heart rate, temperature and arterial oxygen saturation.

At the end of surgery, isoflurane and nitrous oxide were discontinued, residual neuromuscular block was antagonised and the patients were extubated. Postoperative analgesia was achieved with morphine, tramadol and paracetamol.

Being tested
Placebo, Misoprostol
Keywords
Full term pregnancy > 36 weeks, Cesarean delivery, General anesthesia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Also called Group A

    received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.

  • MisoprostolDrug

    Also called Group M

    sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).

Study groups in NCT01466530
Study groupRoleWhat they receive
PlaceboPlacebo comparatorsublingual two moistened white coated placebo tablets
Receives: Drug: Placebo
MisoprostolActive comparatorsublingual misoprostol (400 µg)
Receives: Drug: Misoprostol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. estimated blood loss after caesarean delivery

    estimated blood loss (EBL) = pregnancy blood volume (ml) (EBV) x [preoperative haematocrit - postoperative haematocrit] / preoperative haematocrit, where EBV measured as shown in the following formula; (0.75 x {[maternal height (inches) x 50] + [maternal weight in pounds x 25]})

    Measured: up to 24 hours

Secondary outcomes (5)
  1. uterine tone

    The obstetrician who was blinded to the study group, assessed the uterine tone by palpation every three minutes after delivery of the placenta and rated the degree of uterine contraction on a 10-cm VAS (0: well contracted; 10: completely relaxed).

    Measured: 5 min, 10 min, 15 min, 20 min, 25 min, 30 min

  2. need for additional oxytocin

    If uterine tone remained unsatisfactory for 3 min after delivery, an additional 5-unit bolus of oxytocin was administered. The number of patients received oxytocin was recorded

    Measured: 8 hrs

  3. haematocrit levels

    haematocrit levels was recorded before and 48 hours after cesarean delivery

    Measured: 24 hours, 48 hours

  4. neonatal outcome

    Apgar score and clinical signs after delivery

    Measured: 1 min and 5 min

  5. adverse effects

    the presence of postoperative side effects such as nausea and vomiting, diarrhoea, abdominal pain, pyrexia, and shivering were recorded.

    Measured: 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Nov 2011 (estimated)
  2. Study startJan 2006
  3. Primary completionAug 2011
  4. Study completionSep 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
366 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01466530
Sponsor's protocol ID
2011-2
Status last verified
Nov 2011
First submitted
27 Oct 2011
Last updated
8 Nov 2011
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Misoprostol in people with Pregnancy and Cesarean Delivery, run by Mansoura University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

estimated blood loss after caesarean delivery (time frame: up to 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in